Wavegate, a pioneering developer of neuromodulation technology for chronic pain management, announced it has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners, a London-based investment firm. This funding will accelerate the development of Wavegate’s proprietary Ellipse platform, featuring StimuLux technology, designed to provide breakthrough therapeutic solutions for chronic pain patients.
Wavegate’s Ellipse spinal cord stimulator utilizes optical reflectometry to offer closed-loop adaptive modulation, uniquely adjusting stimulation in real time based on spinal cord movement. This technology—which received the FDA Breakthrough Device designation—offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse platform.
UCEA Capital Partners’ funding aligns with its strategic focus on supporting transformative healthcare technologies. The Series A funding round will be essential in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.
KEY QUOTES:
“Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology. UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.”
- Dr. Erich Wolf, CEO of Wavegate Corporation
“Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need.”
- Joao Teixeira, Chairman of UCEA Capital Partners Ltd
